Kimberly Redmond//July 1, 2025//
PHOTO: DEPOSIT PHOTOS
PHOTO: DEPOSIT PHOTOS
Kimberly Redmond//July 1, 2025//
More than a dozen physicians and pharmacies in New Jersey reached settlements with federal authorities to resolve allegations they defrauded Medicare, Medicaid, TRICARE and private health insurers.
According to the U.S. Attorney’s Office for the District of New Jersey, the accused participated in schemes such as submitting reimbursements for drugs, devices and tests that patients didn’t need or were never sold, as well as receiving kickbacks to drive phony prescriptions.
The June 30 announcement includes pharmacies in Camden, Jersey City, Newark and Elizabeth, along with Newark Beth Israel Medical Center and a dental group, authorities said.
The settlements are also part of a larger crackdown on health care fraud by the Department of Justice that resulted in criminal charges against 324 licensed medical professionals across the U.S. Altogether, the defendants are alleged to have participated in various schemes that resulted in over $14.6 billion in losses, authorities said.
In New Jersey, the U.S. Attorney’s Office said the following individuals were charged and entered settlements:
Charged with conspiracy to violate the federal anti-kickback statute in connection with a scheme to generate referrals for durable medical equipment and cancer genetic tests. As alleged in the indictment:
Charged by information with conspiracy to commit health care fraud in connection with a scheme to submit false and fraudulent claims to Amtrak’s health care plan for services that never provided and medically unnecessary. Amtrak paid approximately $2.25 million on these claims.
Charged by indictment with health care fraud in connection with a scheme to submit fraudulent prescription drug claims to Medicare.
As alleged in the indictment, pharmacy owner Jaime engaged in a scheme to submit fraudulent claims for a high-reimbursement medication that was never dispensed; and for which the pharmacy never received any prescriptions from the purported beneficiaries’ health care providers for the medication.
Medicare paid Jaime’s pharmacy $2.51 million for these false and fraudulent claims.
These predatory schemes prioritize profits over patients, and the District of New Jersey is fiercely committed to rooting out this fraud and ensuring those responsible face justice.
– acting U.S. Attorney Alina Habba
Agreed to pay $250,000 to resolve allegations that from Jan. 1, 2018, through Dec. 31, 2019, doctors working in NBIMC’s Heart Transplant Program failed to adequately disclose to patients and their family members material medical information about patients’ conditions. The United States contends that this conduct resulted in NBIMC performing medically unnecessary treatment on these patients.
“Newark Beth Israel Medical Center (NBI) is dedicated to providing the highest quality care to its patients in a safe and ethical manner,” a RWJBarnabas Health representative told NJBIZ.
“The U.S. Department of Justice and the U.S. Attorney’s Office for the District of New Jersey (Government) and NBI reached a settlement agreement on claims related to the NBI heart transplant program from 2018. This civil settlement is not in any way an admission of wrongdoing or liability on the part of NBI,” the representative continued. “As stated in the settlement agreement, NBI denies the allegations (by the Government) and did not provide unnecessary medical treatment to patients. Furthermore, this matter is completely unrelated to the any of the actions announced by the Government in its omnibus press release.”
Agreed to pay $3 million to resolve allegations that from Jan. 2, 2015, through Jan. 25, 2022, it caused the submission of claims for reimbursement to the Medicare Part D Program and the New Jersey Medicaid Program for drugs never dispensed to beneficiaries.
Agreed to pay $962,821 to resolve allegations that from Jan. 7, 2015, through Jan. 24, 2022, it caused the submission of claims for reimbursement to the Medicare Part D Program and the New Jersey Medicaid Program for drugs never dispensed to beneficiaries.
Agreed to pay $310,000 to resolve allegations that from Jan. 2, 2015, through Jan. 24, 2022, it caused the submission of claims for reimbursement to the Medicare Part D Program and the New Jersey Medicaid Program for drugs never dispensed to beneficiaries.
Agreed to pay $225,000 to resolve allegations that, from Jan. 2, 2015, through Jan. 25, 2022, it caused the submission of claims for reimbursement to the Medicare Part D Program and the New Jersey Medicaid Program for drugs never dispensed to beneficiaries.
Agreed to pay $540,000 to resolve allegations that from Jan. 1, 2021 through July 31, 2023, it submitted or caused the submission of claims for reimbursement to the Medicare Part D Program and the New Jersey Medicaid Program for:
In a statement, acting U.S. Attorney Alina Habba said, “These predatory schemes prioritize profits over patients, and the District of New Jersey is fiercely committed to rooting out this fraud and ensuring those responsible face justice.”
U.S. Attorney General Pamela Bondi added, “This record-setting Health Care Fraud Takedown delivers justice to criminal actors who prey upon our most vulnerable citizens and steal from hardworking American taxpayers. Make no mistake — this administration will not tolerate criminals who line their pockets with taxpayer dollars while endangering the health and safety of our communities.”
Editor’s note: This story was updated at 5:04 p.m. EST July 1, 2025, to remove a reference to Newark Beth Israel pharmacy, which was not among those named. Additionally, the story was updated to include a statement from RWJBarnabas Health.